MS 201408-0005A - EMD Serono

Drug Profile

MS 201408-0005A - EMD Serono

Alternative Names: MS201408-0005A

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Serono
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Oct 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (unspecified route) (NCT03306420)
  • 03 Oct 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Monotherapy) in USA (unspecified route) (NCT03306420)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top